Get started
Author

Irene Garzia

Institution: Nouscom (Italy)
Observed institution: Nouscom (Italy)
ORCID: 0009-0008-3001-2674
Observed ORCID: 0009-0008-3001-2674
OpenAlex ID: A5063622946
A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability
2020 · Guido Leoni, Anna Morena D'Alise, et al. · Cancer Research · 91
Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
2024 · Anna Morena D'Alise, Guido Leoni, et al. · Clinical Cancer Research · 53
PDF
Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial
2026 · Anna Morena D’Alise, Jason Willis, et al. · Nature Medicine · 33
PDF
Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
2020 · Maria De Lucia, Gabriella Cotugno, et al. · Molecular Therapy — Oncolytics · 30
PDF
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
2021 · Anna Morena D'Alise, Guido Leoni, et al. · Journal for ImmunoTherapy of Cancer · 15
PDF
Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2024 · Irene Garzia, Linda Nocchi, et al. · Cancer Immunology Research · 14
PDF
Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer
2023 · Anna Morena D’Alise, Linda Nocchi, et al. · Frontiers in Immunology · 14
PDF
VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction
2021 · Guido Leoni, Anna Morena D’Alise, et al. · Vaccines · 14
PDF
Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity
2023 · Laura Seclì, Luigia Infante, et al. · Journal for ImmunoTherapy of Cancer · 7
PDF
Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model
2025 · Laura Seclì, Linda Nocchi, et al. · Journal for ImmunoTherapy of Cancer · 5
1526 Nous-209 genetic vaccine encoding shared cancer neoantigens is safe and elicits robust immune response in healthy Lynch syndrome carriers: interim results from Phase 1 cancer interception trial
2023 · Morena D’Alise, Jason Willis, et al. · Journal for ImmunoTherapy of Cancer · 5
PDF
Abstract LB196: NOUS-PEV, a personalized cancer immunotherapy targeting neoantigens, induces long lasting, tumor infiltrating memory T cells
2023 · Oliver Bechter, Anna Morena D'Alise, et al. · Cancer Research · 5
Abstract 6427: Nous-209 off-the-shelf neoantigen immunotherapy induces robust neoantigen T cell response with the potential to intercept cancer in Lynch syndrome carriers
2025 · Jason Willis, Anna Morena D'Alise, et al. · Cancer Research · 4
638 Nous-209 vaccine induces shared neoantigen immunogenicity for cancer interception in healthy lynch syndrome carriers: results from phase Ib/II trial
2024 · Eduardo Vilar, Jason Willis, et al. · Journal for ImmunoTherapy of Cancer · 4
706 NOUS-PEV, a novel personalized viral-based prime/boost cancer immunotherapy targeting patient-specific neoantigens: interim results from the first subjects in the phase 1b study
2022 · Oliver Bechter, Juan Martin-Liberal, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine
2024 · Rosa Bartolomeo, Fulvia Troise, et al. · Vaccines · 3
PDF
Abstract B053: Neoadjuvant Personalized Viral Vectored vaccines are highly effective against tumor relapse in checkpoint inhibitor resistant murine models
2024 · Anna Morena D'Alise, Laura Seclì, et al. · Cancer Immunology Research · 1
Data from Phase I Trial of Viral Vector-Based Personalized Vaccination Elicits Robust Neoantigen-Specific Antitumor T-Cell Responses
2024 · Anna Morena D'Alise, Guido Leoni, et al. · 1
Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report
2026 · Marina Crespo-Cruz, Manuel Rodriguez-Justo, et al. · Journal of Immunotherapy and Precision Oncology
Supplementary Figure 5 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2026 · Irene Garzia, Linda Nocchi, et al.
Supplementary Figure 1 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2026 · Irene Garzia, Linda Nocchi, et al.
Supplementary Figure 2 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2026 · Irene Garzia, Linda Nocchi, et al.
Supplementary Figure 6 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2026 · Irene Garzia, Linda Nocchi, et al.
Supplementary Figure 4 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2026 · Irene Garzia, Linda Nocchi, et al.
Supplementary Figure 3 from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine
2026 · Irene Garzia, Linda Nocchi, et al.
Works count: 43
Citation count: 303
H-index: 8
I10-index: 8
Year
Topic
Type